All In Biotech

Drug Trial Radar · NCT04238195

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jan 19, 2020

Primary completion

Feb 26, 2020

Study completion Feb 26, 2020

Sponsor

Lead sponsor
Spero TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Celerion
First posted
Jan 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind (with respect to Tebipenem pivoxil hydrobromide \[TBPM-PI-HBr\]/placebo only), placebo- and active-control, single-dose, 4-way crossover study that will enroll 24 healthy adult male and female subjects. There will be a washout period of at least 7 days between dosing in each period and each subject will receive all 4 treatments over 4 periods in a crossover study design.

Conditions

  • TQT Study

Interventions

  • Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + PlaceboDrug

    Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.

  • Moxifloxacin 400mgDrug

    Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.

  • Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)Other

    Treatment C: Subjects receive TBPM-PI-HBr matching placebo.

  • Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)Drug

    Treatment B: Subjects receive TBPM-PI-HBr.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr on the heart rate corrected QT interval (QTc) by assessing concentration-QT (C-QT) relationship using exposure-response modeling.Time frame: Pre-dose through 24 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.